GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Change In Payables And Accrued Expense

Karolinska Development AB (Karolinska Development AB) Change In Payables And Accrued Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Change In Payables And Accrued Expense?

Karolinska Development AB's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Karolinska Development AB's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Karolinska Development AB's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Karolinska Development AB's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Karolinska Development AB Change In Payables And Accrued Expense Historical Data

The historical data trend for Karolinska Development AB's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB Change In Payables And Accrued Expense Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Karolinska Development AB Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karolinska Development AB Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Karolinska Development AB (Karolinska Development AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
OSTO:MVIR OSTO:NICA OSTO:INDEX OSTO:IVACC OSTO:IRLAB A OSTO:IMMU OSTO:SANION OSTO:GUARD OSTO:INIT OSTO:KAN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KDEV:Sweden 2I9:Germany
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Website
https://www.karolinskadevelopment.com
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.